Rhumbline Advisers Takes $1.37 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Rhumbline Advisers acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 40,835 shares of the biopharmaceutical company’s stock, valued at approximately $1,366,000.

A number of other hedge funds have also recently modified their holdings of the business. Alps Advisors Inc. lifted its stake in Celldex Therapeutics by 1.2% during the first quarter. Alps Advisors Inc. now owns 71,581 shares of the biopharmaceutical company’s stock worth $1,475,000 after purchasing an additional 861 shares during the last quarter. UBS Asset Management Americas Inc. increased its holdings in Celldex Therapeutics by 4.1% during the 1st quarter. UBS Asset Management Americas Inc. now owns 35,377 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 1,390 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Celldex Therapeutics by 67.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,151 shares of the biopharmaceutical company’s stock worth $139,000 after acquiring an additional 1,673 shares during the period. Swiss National Bank grew its holdings in shares of Celldex Therapeutics by 2.1% during the 1st quarter. Swiss National Bank now owns 90,400 shares of the biopharmaceutical company’s stock worth $1,862,000 after acquiring an additional 1,900 shares during the period. Finally, Morgan Stanley grew its holdings in shares of Celldex Therapeutics by 12.6% during the 1st quarter. Morgan Stanley now owns 22,005 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 2,459 shares during the period. 75.77% of the stock is owned by hedge funds and other institutional investors.

In other news, CFO Samuel Bates Martin sold 2,738 shares of Celldex Therapeutics stock in a transaction on Tuesday, August 10th. The shares were sold at an average price of $45.25, for a total transaction of $123,894.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.90% of the stock is currently owned by insiders.

Shares of NASDAQ:CLDX opened at $55.21 on Friday. The company has a market cap of $2.57 billion, a price-to-earnings ratio of -33.06 and a beta of 3.06. Celldex Therapeutics, Inc. has a 12 month low of $11.88 and a 12 month high of $56.17. The company has a 50-day moving average price of $48.75 and a 200 day moving average price of $35.23.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.06. Celldex Therapeutics had a negative net margin of 766.16% and a negative return on equity of 26.76%. The firm had revenue of $3.48 million during the quarter, compared to the consensus estimate of $1.13 million. As a group, equities research analysts predict that Celldex Therapeutics, Inc. will post -1.5 earnings per share for the current fiscal year.

Several analysts recently weighed in on the company. HC Wainwright upped their price target on Celldex Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, September 13th. Jefferies Financial Group began coverage on Celldex Therapeutics in a research report on Friday, September 17th. They issued a “buy” rating and a $66.00 price objective on the stock. Zacks Investment Research raised Celldex Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 3rd. SVB Leerink began coverage on Celldex Therapeutics in a report on Friday, September 10th. They set an “outperform” rating and a $68.00 price target on the stock. Finally, Guggenheim started coverage on Celldex Therapeutics in a report on Thursday, July 22nd. They set a “buy” rating and a $66.00 price target on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $53.00.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Featured Story: Why Invest in Dividend Kings

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.